Glioma and temozolomide induced alterations in gut microbiomeOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined how glioma tumors and temozolomide (TMZ) chemotherapy each affect the gut microbiome. They compared fecal microbiota in a GL261 mouse glioma model and in human glioma patients versus healthy controls.
How was it studied?
C57BL/6 mice received GL261 tumor implants or sham surgery, then TMZ or saline, with longitudinal fecal 16S rRNA sequencing. Human fecal samples came from healthy controls and glioma patients at diagnosis, and before and after chemoradiation.
What did they find?
Glioma mice and glioma patients both showed altered beta diversity, a shifted Firmicutes/Bacteroides ratio, and increased Verrucomicrobia phylum and Akkermansia genus versus healthy controls. TMZ alone did not reproduce these changes; instead it lowered the Firmicutes/Bacteroides ratio, increased Muribaculaceae, and decreased Ruminococcaceae, without affecting Verrucomicrobia or Akkermansia.
Why it matters
The findings suggest glioma itself, rather than TMZ chemotherapy, is the main driver of gut dysbiosis, with mouse findings appearing to translate to human patients. The authors say further study is warranted.